Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera Assay in China

▴ Natera and BGI Genomics Announce Launch of the BGI/Natera Signatera
Natera and BGI Genomics entered into a partnership to commercialize Natera’s Signatera test in China

Natera, Inc., a pioneer and global leader in cell-free DNA (cfDNA) testing, and BGI Genomics Co., Ltd., one of the world’s leading genomics companies, recently announced the launch of the BGI/Natera Signatera Assay which is now available to biopharmaceutical customers and clinicians across China.

Natera’s Signatera assay, now offered in partnership with BGI,1 has been utilized in numerous clinical studies across non-small cell lung, bladder, breast, and colorectal cancers, to identify the molecular residual disease (MRD) up to two years earlier than standard imaging. The test is now available in China under the Chinese brand name  (Hua Jian Wei for short).

"We’re excited to bring this revolutionary technology to clinicians and patients in China," said John Fesko, the chief business officer at Natera. "Partnering with BGI also enables Natera to offer our pharma partners truly global clinical trial services."

In March 2019, Natera and BGI Genomics entered into a partnership to commercialize Natera’s Signatera test in China,1 and after two years of technology transfers and validation, the BGI/Natera Signatera Assay is now officially available in the country. The assay can help facilitate the innovative trial design and enable biopharmaceutical researchers to make better informed and more timely decisions. Pharmaceutical companies can access this assay in China through the BGI-Natera partnership, which offers unique opportunities for companion diagnostic registration in both China and the U.S.

"BGI is committed to promoting precision medicine and cancer prevention with cutting-edge technologies. Signatera can detect recurrence earlier and help clinicians optimize treatment decisions, thus bringing greater survival benefits for patients. In partnership with Natera, we are pleased to introduce Signatera into China and provide this innovative technology that incorporates MGI sequencing platforms for clinical oncology and drug development in a reliable and affordable manner," said Shida Zhu, general manager of BGI Oncology.

Tags : #Natera #LatestNewsonNatera28thJune #BGIGenomics #LatestNewsonBGIGenomcs28thJune #LatestPharmaCollaboration28thJune #Cancer

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026